TP53BP2 and pancreatic neoplasm: It was reported that inhibition of autophagy can increase chemotherapy-induced apoptosis in hepatocarcinoma cells,[41] colon cancer,[42] and esophageal cancer cells.[43] In our study, we found that the decrease of ASPP2 could enhance the autophagic activity of pancreatic cancer cells, and this lead to pancreatic cancer cells less sensitive to gemcitabine induced cell apoptosis in vitro and in vivo; Lower expression of ASPP2 was also correlated with poor outcome of gemcitabine treatment and survival rates.